2,500
Participants
Start Date
October 20, 2023
Primary Completion Date
December 1, 2025
Study Completion Date
December 31, 2025
Phase C: Eplerenone
Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
Phase C: Spironolactone
Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
Phase C: Torasemide
Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
Phase B: Triplixam / Elestar HCT
Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
Phase A: Confirmation of uncontrolled hypertension
Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
RECRUITING
National Institute of Cardiology, Warsaw
National Institute of Cardiology, Warsaw, Poland
OTHER